Q2 2025 EPS Estimates for Replimune Group, Inc. (NASDAQ:REPL) Increased by Analyst

Replimune Group, Inc. (NASDAQ:REPL) – Investment analysts at HC Wainwright lifted their Q2 2025 earnings estimates for Replimune Group in a report issued on Tuesday, September 10th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.77) per share for the quarter, up from their previous estimate of ($0.86). HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Replimune Group’s current full-year earnings is ($3.08) per share. HC Wainwright also issued estimates for Replimune Group’s Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.82) EPS and FY2025 earnings at ($3.16) EPS.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.10.

A number of other brokerages have also recently commented on REPL. Roth Mkm initiated coverage on Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price for the company. Barclays boosted their price objective on shares of Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. JPMorgan Chase & Co. lowered their target price on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Finally, Wedbush reissued an “outperform” rating and issued a $16.00 price objective on shares of Replimune Group in a research report on Thursday, June 6th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $16.20.

Replimune Group Trading Up 7.2 %

Shares of NASDAQ REPL opened at $11.13 on Thursday. Replimune Group has a 1-year low of $4.92 and a 1-year high of $19.16. The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. The business’s 50 day moving average is $10.05 and its two-hundred day moving average is $8.34. The stock has a market capitalization of $683.55 million, a P/E ratio of -3.44 and a beta of 1.22.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its position in Replimune Group by 517.9% during the 4th quarter. BNP Paribas Financial Markets now owns 196,251 shares of the company’s stock valued at $1,654,000 after purchasing an additional 164,490 shares in the last quarter. Clearbridge Investments LLC purchased a new stake in Replimune Group in the fourth quarter worth about $2,282,000. Quest Partners LLC purchased a new stake in Replimune Group in the fourth quarter worth about $76,000. Rafferty Asset Management LLC grew its holdings in Replimune Group by 148.1% during the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock worth $3,906,000 after acquiring an additional 276,596 shares in the last quarter. Finally, Sectoral Asset Management Inc. increased its position in Replimune Group by 12.7% during the 4th quarter. Sectoral Asset Management Inc. now owns 305,412 shares of the company’s stock valued at $2,575,000 after purchasing an additional 34,356 shares during the period. Institutional investors own 92.53% of the company’s stock.

Insider Activity

In related news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the transaction, the chief financial officer now owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 20.60% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.